Cephalon Looks For Growth as Nuvigil Fails Schizophrenia Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
With sales leader Provigil slated to lose patent protection in 2012, specialty pharma also is looking beyond Nuvigil for answers.
You may also be interested in...
Cephalon’s Nuvigil For Jet Lag Is Pulled Off The Runway; Bipolar Indication Remains On The Horizon
After dropping efforts to obtain approval of Nuvigil (armodafinil) for treatment of jet lag disorder, Cephalon is left with one possible new indication for the wakefulness drug: depression associated with bipolar disorder.
Cephalon’s Nuvigil For Jet Lag Is Pulled Off The Runway; Bipolar Indication Remains On The Horizon
After dropping efforts to obtain approval of Nuvigil (armodafinil) for treatment of jet lag disorder, Cephalon is left with one possible new indication for the wakefulness drug: depression associated with bipolar disorder.
Cephalon's Buchi Steps In To Fill Baldino's Big Shoes
Founder and CEO Frank Baldino is taking a temporary medical leave of absence, but the company says he will be back before the end of the year.